Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues.

target complexes. These molecular glue stabilizers amplify native biology to restore or inhibit target function, potentiate target activity, or promote or block target degradation. Ambagon’s initial focus is on oncology, with five programs in discovery. It has locations in San Carlos, California, and Eindhoven, the Netherlands.

Ambagon Therapeutics Launches With $85 Million Series A To Advance Pioneering Molecular Glue Platform And Progress Pipeline

Ambagon Therapeutics Launches With $85 Million Series A To Advance Pioneering Molecular Glue Platform And Progress Pipeline

Company Info